172 results about "Nephropathy" patented technology

The invention provides application of a product of targeted Vasorin protein in preparation of a product for diagnosing or treating kidney diseases with reduced glucose tolerance, and belongs to the technical field of biological medicines. Vasorin is used as a biomarker of the hypoglucose tolerance nephropathy, the level of Vasorin in urine of a patient is absolutely quantified through an ELISA technology, and the Vasorin has great clinical value and practical significance in early discovery and intervention of the hypoglucose tolerance nephropathy. According to the present invention, the gene or the Vasorin protein for controlling the Vasorin expression is adopted as the target spot, and the specific vector is adopted to perform overexpression on the Vasorin protein, such that the lipid droplet deposition and the reactive oxygen species (ROS) overgeneration in the renal tubular epithelial cell can be effectively improved, and the albumin reabsorption ability of the renal tubular can be improved so as to effectively treat the glucose tolerance reduced nephropathy.

According to various aspects of this disclosure, the present disclosure relates to methods for reducing kidney inflammation, reducing kidney fibrosis, reducing oxidative stress in the kidney, preventing or reducing the likelihood of chronic kidney disease (CKD), treating or preventing acute kidney injury (AKI) or treating a kidney disease in a subject in need thereof comprising administering, e.g., intramuscularly, to the subject a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV vector comprises a vector genome comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or a functional fragment thereof and an AAV capsid (e.g., AAV1 serotype), optionally, wherein the subject does not suffer from diabetes.

The invention relates to proteins for use in the prevention, treatment or amelioration of kidney diseases or kidney damage, more particularly where the protein is a follistatin-fusion protein.

The invention discloses a method for constructing a pressed butterfly mycin glycoside gene engineering strain by using glycosyl transferase and application of the pressed butterfly mycin glycoside gene engineering strain. A strong promoter kasOp * is introduced to the upstream of a glucoside transferase gene pie28 of Streptomyces psammoticus SCSIO NS126, the nucleotide sequence of the strong promoter kasOp * is as shown in SEQ ID NO. 1, and the nucleotide sequence of the glucoside transferase pie28 is as shown in SEQ ID NO. 2. The invention also discloses a preparation method of the Streptomyces psammoticus SCSIO NS126, and the preparation method of the Streptomyces psammoticus SCSIO NS126 comprises the following steps of: introducing the strong promoter kasOp * into the upstream of the glucoside transferase gene pie28. The streptomyces gene engineering strain Streptomyces sp. SK-kas28 constructed by the invention can efficiently express the chalcone glycoside, is widely applied to fermentation production of the chalcone glycoside, and is used for research and development of new drugs for treating kidney diseases and the like.

Use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof or an isotopically labeled compound thereof in the preparation of a drug for preventing or treating neurodegenerative diseases, autoimmune and systemic inflammatory diseases, metabolic and cardiovascular diseases, respiratory diseases, ophthalmic diseases, or kidney diseases.

Provided herein are compounds that are useful in treating cancer, metabolic disease, cardiovascular disease, and kidney disease.

The present invention provides methods of using non-naturally occurring melanocortin analogs to increase body weight and / or increase food consumption in a subject having a kidney disease and / or a liver disease (e.g., chronic kidney disease, renal failure, non-alcoholic fatty liver disease (NAFLD)). Also provided are methods of stimulating appetite in a subject via administration of a non-naturally occurring melanocortin analogue. The non-naturally occurring melanocortin analogs may be present in pharmaceutical compositions and delivered via parenteral administration (e.g., subcutaneous injection). The methods improve appetite, increase food consumption, increase body weight, muscle mass, and / or fat mass in the subject.

The present application relates to the technical field of pharmaceutical analysis, and in particular to a combined analysis method for exploring the effect of Huangkui capsules on improving chronic kidney injury of tacrolimus based on metabolomics and proteomics. The combined analysis method of the present application explores how Huangkui capsules improve the mechanism of chronic kidney injury of tacrolimus from multiple dimensions, which is beneficial to in-depth analysis of the specific effects of Huangkui capsules at the molecular, cellular and tissue levels, reveals the key path and regulation mechanism of kidney protection, and can also provide a scientific basis for optimizing clinical application, further promoting the modernization of traditional Chinese medicine and its wide application in the treatment of kidney disease.

The invention relates to a specifically degraded KIM1 liposome, preparation thereof and application of the specifically degraded KIM1 liposome in preparation of medicines for treating kidney diseases, and belongs to the technical field of biological medicines. According to the invention, a KIM1 targeting polypeptide and an E3 ubiquitin ligase ligand (such as lenalidomide) are respectively modified on the surface of a liposome. The lipidosome capable of specifically degrading the KIM1 can be rapidly enriched in a damaged kidney after renal injury occurs, and the KIM1 protein level in the damaged kidney is degraded by 75%. Meanwhile, the druggability problems of poor solubility, low bioavailability and the like caused by large molecular weight of the compound in the PROTAC drug development process are avoided, and the technical problems that drugs are difficult to prepare and kidney injury drugs are lacked in the prior art are solved.

We provide TRPC5 inhibitors for use in treating or reducing the risk of developing kidney disease, diabetic retinopathy, anxiety disorders, depression, or cancer. [Solution] Compounds according to formula (I) or (II), and pharmaceutical compositions containing them are disclosed. A therapeutic method using a compound of formula (I) or (II) to treat, for example, kidney disease is also disclosed. JPEG2026086459000081.jpg3992

The application belongs to the field of biological detection, and particularly relates to a technology and a reagent for detecting NAG by a VRA-NAG substrate method. The linear range of the NAG detection reagent provided by the application can reach (0, 500] U / L; within the range, when the anti-acid is less than or equal to 340 micromoles / L, urea is less than or equal to 42.9 millimoles / L, uric acid is less than or equal to 1.4 millimoles / L, albumin is less than or equal to 100 milligrams / dL, bilirubin is less than or equal to 342 micromoles / L, lactic acid is less than or equal to 6.6 millimoles / L, glucose is less than or equal to 55 millimoles / L, triglyceride is less than or equal to 37 millimoles / L, and oxalic acid is less than or equal to 81 micromoles / L, these components have no obvious interference on the test. Moreover, the relative standard deviation caused by the accelerated aging of the detection reagent for 10 days is not more than ±10%. Compared with the prior art, the kit provided by the application has high sensitivity, wide linear range, strong specificity and good stability, and is conducive to early detection and early treatment of kidney diseases in clinical practice.

The present application relates to the technical field of medical information processing, in particular to an abnormal event automatic classification and recording method in a kidney disease follow-up system, comprising collecting kidney function parameters and symptom codes, identifying abnormal sequences, extracting time anchor points and characteristic identifiers, calculating flip frequency and amplitude, constructing a feature vector to evaluate risk and generating event classification records. In the present application, by constructing an abnormal trigger ordered sequence and extracting anchor points to determine composite features, combining symptom flip frequency to construct a persistence intensity coefficient, quantifying disease complexity from the dimensions of time evolution and etiology coupling, using a multi-dimensional feature vector to fuse physiological amplitude and statistical characteristics, obtaining disease risk probability values through weighted calculation, realizing the transition from qualitative classification to quantitative risk grading, solving the false alarm and missed alarm problems caused by single index determination, providing dynamic diagnosis basis containing risk level for clinical, significantly improving the recognition accuracy and intervention timeliness of the hidden deterioration trend in kidney disease follow-up.

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and / or transforming growth factor β1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.

Described herein are treatment regimens, therapies, pharmaceutical formulations and methods of using quercetin to prevent, treat, and / or protect from muscle wasting including 1) sarcopenia associated with aging; and 2) cachexia associated with chronic diseases and their treatments including but not limited to cancer, cardiovascular disease, chronic obstructive pulmonary disease (COPD), HIV, and kidney disease.

The present invention relates to methods of immunoassay for detecting a biomarker which is an MMP-cleaved fragment of collagen type-I and its use in detecting and / or monitoring diseases such as kidney disease and diseases of the cardiovascular system including the heart.

The present application relates to the precise treatment of kidney disease and the detection technology of intestinal micro-ecological biomarkers, in particular to a biomarker for rapidly screening kidney disease patients treated by leflunomide and application thereof.The present application provides a biomarker for rapidly screening kidney disease patients treated by leflunomide, which can accurately identify whether the patient is an IgAN patient after leflunomide treatment, so as to guide the subsequent medication of the IgAN patient.The results of the specific embodiment of the present application prove that the area under the curve is 0.903, the specificity is 0.83, and the sensitivity is 0.86.

This invention discloses a reactive oxygen species (ROS)-responsive nanocomposite for targeting and repairing damaged endothelium, its preparation, and its application, belonging to the field of nanomedicine technology. The nanocomposite comprises a physalicylate-copper nanoparticle core and a P-selectin-targeting polypeptide linked to the core surface via thiol-copper affinity. The physalicylate-copper nanoparticle core is prepared by coordination of physalicylate and copper ions to form a primary complex, followed by ascorbic acid reduction. This composite nanosystem can specifically recognize and accumulate in the blood vessels and peritubular regions of the kidney injury area, releasing Cu in response to high concentrations of ROS in an inflammatory environment. 2+ Together with HBT, it simultaneously achieves antioxidant and anti-inflammatory functions, promotes angiogenesis and repair, and inhibits the release of inflammatory factors and macrophage infiltration and activation, effectively blocking the fibrosis process. This system has a well-defined structure and strong targeting, and can effectively rebuild microvessels, reduce inflammation, and block the process of renal fibrosis, providing a highly efficient and precise new nanomedicine strategy for the anti-fibrotic treatment of kidney diseases.

The invention belongs to the technical field of kidney disease treatment and diagnosis, discloses kidney disease treatment and diagnosis with TRAP5 as a target spot, and particularly discloses application of a TRAP5 inhibitor in preparation of a medicine for treating kidney diseases and application of a kit for detecting TRAP5 protein and / or Acp5 mRNA in kidney disease diagnosis and / or evaluation. The invention confirms the existence of scar-related macrophages (SM) with high expression of TRAP5 in the progress process of renal interstitial fibrosis and acute kidney injury (AKI) to chronic kidney disease (CKD), and provides a TRAP5 inhibitor taking the scar-related macrophages with the expression of TRAP5 as a treatment target and a kit for detecting TRAP5 protein and / or Acp5 mRNA. The treatment and diagnosis of the chronic kidney diseases with various renal interstitial fibrosis as the main characteristic are realized, and a new treatment strategy and a new drug target are provided for AKI-CKD transformation and related fibrosis diseases.

The invention provides a composite plant polypeptide composition for reducing blood glucose, repairing cells, resisting oxidation and enhancing immunity as well as a preparation method and application thereof, and belongs to the technical field of biology. The invention provides a composition. Comprising a protein peptide composed of millet protein peptide, soybean protein isolate peptide, whey protein peptide and sea buckthorn protein peptide, dietary fiber composed of chia seed powder and konjaku flour, a probiotic compound composed of bifidobacterium lactis BB-12 and lactobacillus rhamnosus LGG, fructo-oligosaccharide, balsam pear peptide, a cyclocarya paliurus extract, a corn stigma extract, a mulberry leaf extract, a vitamin E extract, a vitamin E extract, a vitamin E extract, a vitamin E extract, a vitamin E extract and a vitamin E extract. The extract mixture is composed of a radix puerariae extract, a rhizoma polygonati polysaccharide extract, a moringa oleifera leaf extract and leech powder, and the vitamin mineral substance mixture is composed of other functional components. The composition provided by the invention is matched with various proteins, dietary fibers, probiotics, prebiotics, plant extracts, vitamins, minerals, other functional components and the like, so that the purpose of effectively and synergistically improving the conditions of diabetes and nephropathy from multiple targets and multiple ways is finally achieved.

The invention provides a preparation process and a use method of a medicinal and edible substance composition. The medicine overcomes the defects that rejection reaction is insufficient when cancer is treated by a stem cell transplantation method and organ lesions cannot be treated simultaneously when cancer is treated by an immune cell method and a vaccine cell method; the oral liquid comprises the following raw materials in parts by weight: 0.1-3.0 parts of cordyceps militaris, 0.1-3.0 parts of fermented cordyceps sinensis powder, 1.0-3.5 parts of pseudo-ginseng, 1.0-2.5 parts of American ginseng, 1.0-1.5 parts of salvia miltiorrhiza powder or ligusticum wallichii, 1.0-3.0 parts of high-quality gastrodia elata and medicinal pure honey which is 0.9-1.3 times of the total weight of the medicinal materials. The preparation method comprises the following steps: mixing prescription raw materials, crushing, adding honey, and preparing honeyed boluses or beverages. The medicine disclosed by the invention is safe, can treat cancers, diabetes mellitus, heart diseases, liver diseases, nephropathy, uremia or entanglement of a plurality of diseases with high curative effect, and enables patients to be young; according to the invention, messy code genes of a patient can be normally edited while the disease is treated.

The present disclosure relates to methods related to the treatment of B-cell responsive autoimmune glomerulopathies.

Methods of treating type 1 diabetes, improving cardiovascular health, delaying renal function decline, reducing the risk of cardiovascular death and reducing the risk of heart failure hospitalization, while minimizing adverse events such as diabetic ketoacidosis and severe hypoglycemia, using sodium-glucose cotransporter 2 (SGLT2) inhibitors are disclosed. In a preferred method, the SGLT2 inhibitor is sofogliflozin. Also disclosed are prescriptions for developing sofogliflozin and methods of administering sofogliflozin.

The application discloses application of benzoyl oxypaeoniflorin in preparation of a medicine for preventing or treating FABP4 high-expression related kidney diseases. It is found for the first time that the benzoyl oxypaeoniflorin can effectively prevent or treat FABP4 high-expression related kidney diseases, especially renal interstitial fibrosis, by inhibiting a FABP4 target.

This invention relates to an activator of FXR, which can be used to treat autoimmune diseases, liver diseases, intestinal diseases, kidney diseases, cancer, and other diseases in which FXR plays a role, and has the formula (I): wherein L1, A, X1, X2, R 1 R 2 and R 3 As described in this article.

The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof that inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Sustained-release oral pharmaceutical compositions comprising the pharmaceutical composition are described, as well as sustained-release injectable pharmaceutical compositions comprising the pharmaceutical composition.The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal administration comprising the pharmaceutical composition. Also described are: methods for evaluating the efficacy of the pharmaceutical composition; methods for evaluating the inhibitory or partial inhibitory activity of the pharmaceutical composition; methods for treating, alleviating, or preventing a condition or disease comprising administering a therapeutically effective amount of the pharmaceutical composition to a subject; and the use of the pharmaceutical composition for manufacturing a pharmaceutical dosage form for the treatment of a disease.

Methods and kits for assessing the propensity of developing urolithiasis, kidney disease, or bladder disease in pets; and compositions to treat such conditions are described herein.

This invention discloses a butyrate prodrug co-assembled with artesunate, its preparation method, and its application in kidney diseases, belonging to the field of biomedical technology. The invention first uses docosahexaenoic acid (DHA) as a hydrophobic framework, coupling it with 2,2'-dithiodiethanol to introduce disulfide bonds, and then grafts butyrate via esterification to obtain a butyrate prodrug. The butyrate prodrug and artesunate self-assemble through non-covalent interactions to obtain a co-assembled drug in nanoparticle form. This nanomedicine possesses excellent long-term in vivo circulation and passive targeted accumulation in the kidneys, and can achieve targeted drug release in response to the high-glutathione microenvironment within lesion cells. The two active ingredients synergistically exert metabolic regulation, anti-inflammatory, and antioxidant effects, inhibiting kidney inflammation and oxidative stress at multiple targets, protecting renal tubular epithelial cells, and effectively intervening in the pathological process of acute kidney injury. Furthermore, this drug has high biosafety, is simple to prepare, and is easy to scale up, showing broad application prospects in the prevention and treatment of kidney diseases.

According to the application of the reagent for detecting the phosphorylation level of the S202 and T205 sites of the MAPT protein in preparation of the renal fibrosis diagnosis product, the function research of the MAPT protein is expanded from the traditional field of glomerular podocytes to renal tubular epithelial cells and the fibrosis pathological process of the renal tubular epithelial cells for the first time, and a brand new direction of the MAPT protein in renal disease research is opened up. Different from the conventional general research means which only depends on overall gene knockout or overexpression, the method provided by the invention realizes accurate analysis of the function of the MAPT key phosphorylation site by using the site-specific mutant. Through a systematic function determination experiment, the invention discloses an anti-intuition biological rule with great theoretical significance: although phosphorylation of the sites S202 and T205 obviously drives the fibrosis process of the renal tubular epithelial cells, the fibrosis phenotype cannot be improved by simulating the dephosphorylation state (S202A / T205A mutant) of the sites.

The invention relates to the fields of therapy and drug delivery. It is based on an unexpected finding that a combination of an oligonucleotide-based medicament with a saponin component comprising a penta-cyclic triterpene saponin of a 12,13-dehydrooleanane aglycone core, not only does not appear to be associated with oligonucleotide medicament-induced nephrotoxic effects after systemic administration in vivo, but also that it allows the oligonucleotide-based medicament to enter and act on its nucleic acid target inside of the kidney cells instead of remaining unproductively trapped in renal subcellular compartments or being eliminated into the urine via the renal glomerular filtration system. In line with this finding, herein disclosed are therapeutic combinations, compositions, and formulations, as well as methods of treatment involving their administration, which comprise an oligonucleotide-based medicament that acts on an intracellular nucleic acid target in the kidney cells and / or in the cells of the spleen, being the other blood filtering organ in addition to the kidney, and a saponin component that enables the effective release of said medicament inside of these cells, thus allowing its use at a much lower and safer dose. The provision of the presented herein therapeutic combinations enables effective modulation of gene expression in the kidney and / or spleen cells and, therefore, it opens not only new treatment options for kidney diseases, in particular those involving inflammation and / or splenomegaly, but also for diseases of other organs which affect or are affected by the pathological processes happening in the kidneys and / or in the spleen, in particular being inflammatory processes.

This application relates to the technical field of kidney disease, and more particularly to a traditional Chinese medicine (TCM) device for the permeation therapy of kidney disease. The device includes a housing, a fixed plate, and a floating mechanism. The fixed plate is disposed on the inner wall of the housing. Multiple floating mechanisms are arranged in a circular array on the fixed plate. Each floating mechanism includes an ultrasonically conductive silicone pad, a limiting ring, a limiting groove, a first vibrating head, a guide ring, a guide cylinder, and a first spring. The ultrasonically conductive silicone pad is disposed inside the fixed plate, and the limiting ring is disposed on the outer wall of the ultrasonically conductive silicone pad. This embodiment of the TCM device for the permeation therapy of kidney disease utilizes a floating mechanism. Multiple floating mechanisms are arranged in a circular array, each group equipped with an ultrasonically conductive silicone pad, a first vibrating head, a guide cylinder, and a first spring. This allows for slight axial floating, conforming to the physiological curve of the human lumbar region.